公开(公告)号：US20180021480A1

公开(公告)日：2018-01-25

申请号：US15705809

申请日：2017-09-15

Applicant: Teoxane

Inventor： FRANCOIS BOURDON ,  Stephane Meunler

IPC: A61L27/54 ,  A61K9/00 ,  A61K31/167 ,  A61K8/73 ,  A61K31/728 ,  A61K31/16 ,  A61L27/20 ,  A61K31/451 ,  A61Q19/08 ,  A61K47/02 ,  A61K31/445 ,  A61L27/12 ,  A61K8/24 ,  A61K8/49

CPC classification number: A61L27/54 ,  A61K8/24 ,  A61K8/4926 ,  A61K8/735 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/16 ,  A61K31/167 ,  A61K31/445 ,  A61K31/451 ,  A61K31/728 ,  A61K47/02 ,  A61K2800/524 ,  A61K2800/75 ,  A61K2800/91 ,  A61L27/12 ,  A61L27/20 ,  A61L2300/204 ,  A61L2300/402 ,  A61L2400/06 ,  A61Q19/08 ,  A61K2300/00

Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

公开(公告)号：US20180169304A1

公开(公告)日：2018-06-21

申请号：US15895220

申请日：2018-02-13

Applicant: Teoxane

Inventor： FRANCOIS BOURDON ,  Stephane Meunier

IPC: A61L27/54 ,  A61K9/00 ,  A61K8/24 ,  A61K31/451 ,  A61L27/20 ,  A61L27/12 ,  A61K31/445 ,  A61K47/02 ,  A61Q19/08 ,  A61K8/49 ,  A61K31/16 ,  A61K8/73 ,  A61K31/167 ,  A61K31/728

CPC classification number: A61L27/54 ,  A61K8/24 ,  A61K8/4926 ,  A61K8/735 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/16 ,  A61K31/167 ,  A61K31/445 ,  A61K31/451 ,  A61K31/728 ,  A61K47/02 ,  A61K2800/524 ,  A61K2800/75 ,  A61K2800/91 ,  A61L27/12 ,  A61L27/20 ,  A61L2300/204 ,  A61L2300/402 ,  A61L2400/06 ,  A61Q19/08 ,  A61K2300/00

Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

公开(公告)号：US20190184065A1

公开(公告)日：2019-06-20

申请号：US16282598

申请日：2019-02-22

Applicant: Teoxane

Inventor： FRANCOIS BOURDON ,  Stephane Meunier

IPC: A61L27/54 ,  A61K47/02 ,  A61Q19/08 ,  A61K31/728 ,  A61K31/16 ,  A61K8/49 ,  A61K31/167 ,  A61L27/20 ,  A61L27/12 ,  A61K9/00 ,  A61K8/24 ,  A61K8/73 ,  A61K31/445 ,  A61K31/451

CPC classification number: A61L27/54 ,  A61K8/24 ,  A61K8/4926 ,  A61K8/735 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/16 ,  A61K31/167 ,  A61K31/445 ,  A61K31/451 ,  A61K31/728 ,  A61K47/02 ,  A61K2800/524 ,  A61K2800/75 ,  A61K2800/91 ,  A61L27/12 ,  A61L27/20 ,  A61L2300/204 ,  A61L2300/402 ,  A61L2400/06 ,  A61Q19/08 ,  A61K2300/00

Abstract: A sterile composition for intraepidermal, intradermal, and/or subcutaneous administration including an effective amount of hyaluronic acid or a salt thereof, the effective amount of hyaluronic acid or salt thereof ranging from 1 to 3 wt % of the overall weight of the sterile composition, mepivacaine or a salt thereof as a first anesthetic agent at a concentration ranging from 0.05 to 3 wt % of an overall weight of the sterile composition, and a balanced salt solution in which the sterile composition exhibits greater stability over time and/or during heat treatment resulting in sterilization in comparison to the same composition having lidocaine as the anesthetic agent instead of mepivacaine.